The mammalian HMG-I, HMG-Y, and HMGI-C proteins are members of the HMGI(Y) family of nonhistone chromatin proteins that have been implicated in both positive and negative regulation of gene transcription in vivo (reviewed in references 14 and 96) . The human HMG-I (11.5-kDa) and HMG-Y (10.4-kDa) proteins are produced by translation of alternatively spliced mRNAs coded for by the Hmgiy gene at chromosomal locus 6p21 (39) , while the related, but distinct, HMGI-C protein (12 kDa) is coded for by the Hmgi-c gene at chromosomal locus 12q15 (15) . Members of the HMGI(Y) family are often referred to as architectural transcription factors because of their ability to regulate gene activity through the recognition and alteration of the structure of DNA and chromatin substrates (14, 100) . The HMGI(Y) proteins not only bind with high specificity to the narrow minor groove of A ⅐ T-rich, random sequence B-form DNA (97, 107) but also have the ability to bind with high affinity to bent or distorted DNA structures such as synthetic four-way junction DNAs (55, 56) , supercoiled plasmid substrates (87) , and nucleosome core particles (98, 100) . The ability of the HMGI(Y) proteins to bind to a variety of DNA substrates is a consequence of the high degree of intrinsic flexibility of the proteins, particularly within their A ⅐ T hook DNA-binding motifs (97) whose structure in a cocomplex with a synthetic substrate has recently been determined (61) . In addition to recognizing structure rather than sequence, the HMGI(Y) proteins also have the ability to bend, straighten, unwind, and supercoil DNA substrates (14, 33, 75, 87) . It is this unusual combination of substrate-binding characteristics, combined with the ability to specifically interact with other transcription factors, that allows the HMGI(Y) proteins to function as gene-regulatory factors in vivo by participating in the formation of stereospecific multiprotein enhanceosome complexes (66, 122) . Among the known transcription factors that interact with HMGI(Y) in vitro or in vivo are NF-B, ATF-2/c-Jun, Elf-1, Oct-2, Oct-6, SRF, NF-Y, PU-1, RAR, Sp1, NFAT, and others (14, 19, 24, 57, 58, 66, 86, 121) . Their many potential protein partners provide the HMGI(Y) proteins with considerable flexibility in regulating the transcriptional activity of a large number of different genes in vivo (14) , among which some, such as the intercellular adhesion molecule E-selectin (77) , often exhibit aberrant expression patterns in human malignancies (6) whereas others, such as tumor necrosis factor beta (35) and beta interferon (IFN-␤) (83) , are associated with angiogenesis, a necessary component of solidtumor formation.
The level of expression of HMGI(Y) mRNAs and proteins is low (68, 69, 82) or undetectable (40, 44) in most differentiated or nonproliferating normal cells but is rapidly induced in response to growth-stimulatory factors such as serum (67, 69) , transforming growth factor ␣ (TGF-␣) (95) , epidermal growth factor (EGF) (59) , platelet-derived growth factor, and fibroblast growth factor (FGF) (74) , as well as phorbol esters (22, 39) , beta 1 interferon (IFN-␤1), and endotoxin (91) . These observations, combined with the fact that deletion of the Hmgi-c gene results in the diminutive pygmy phenotype in mice (7) , implicate the HMGI(Y) proteins in the control of cell proliferation. Consistent with this suggestion, in neoplastically transformed cells, as well as in embryonic cells that have not yet undergone overt differentiation, the constitutive level of HMGI(Y) gene products is often exceptionally high, with increasing concentrations being correlated with increasing degrees of malignancy or metastatic potential (14, 40, 44, 116) . This correlation is so consistent and widespread in tumors that it has been suggested that elevated concentrations of HMGI (Y) proteins are diagnostic markers of both neoplastic transformation (43, 44) and increased metastatic potential (13, 117) . For example, HMGI(Y) overexpression has been suggested to be a diagnostic indicator for human prostate tumors (118) , thyroid neoplasia (18) , uterine cervix cancers (4) , and colorectal cancers (1) , among others (reviewed in reference 116).
Of particular interest for the present study is the fact that increased expression of HMGI(Y) proteins has been correlated with the increased metastatic potential of both mouse (94, 95) and human (59, 79) mammary epithelial cancers. Importantly, HMGI(Y) overexpression has also recently been detected in primary human breast cancers by a combination of serial analysis of gene expression and array technologies (85, 92) . Overexpression of full-length HMGI(Y) proteins induces anchorage-independent growth of both mouse breast epithelial cells (94) and Rat-1 fibroblast cells (132) in soft agarose, as does overexpression of either truncated or chimeric forms of the HMGI-C protein in murine fibroblasts (37) . Furthermore, antisense-mediated suppression of HMGI(Y) protein synthesis suppresses retrovirus-induced neoplastic transformation of rat thryoid cells (8) , as well as inducing apoptotic death in anaplastic human thyroid carcinoma cell lines but not in normal thyroid cells (102) . Of additional interest is the fact that chromosomal rearrangements in which the A ⅐ T hook DNA-binding domains of the HMGI(Y) proteins are fused to ectopic peptide sequences to form chimeric oncogenic proteins are among the most common lesions in human cancer, being observed in a high percentage of benign mesenchymal neoplasias, including lipomas, leiomyomas, fibroadenomas, aggressive myxomas, pulmonary hamartomas, and endometrial polyps (reviewed in references 54 and 116) . These previous studies, when considered together, present a compelling case for involvement of the HMGI(Y) proteins, and their A ⅐ T hook DNA-binding motifs, in both neoplastic transformation and metastatic tumor progression. Nevertheless, they did not directly and unambiguously demonstrate a causal in vivo relationship between the HMGI(Y) proteins and cancer in intact organisms. These previous studies also did not elucidate the molecular events underlying the biological consequences that overexpression or aberrant expression of HMGI(Y) proteins might have on processes such as oncogenic transformation, increased tumor metastatic potential, and aggressive neoplastic malignancy.
In the present study, we demonstrated that nontumorigenic human breast epithelial cells containing either a tetracyclineregulated HMG-I or HMG-Y transgene acquire the abilities to both grow anchorage independently in soft agar and form metastatic tumors when injected into nude mice only when the HMGI(Y) proteins are overexpressed. While overexpression of either the HMG-Y or HMG-I protein alone readily induced neoplastic transformation, as evidenced by the acquired ability of cells to grow in soft agar, somewhat surprisingly, only the HMG-Y isoform elicited efficient tumor formation and metastasis in vivo when expressing cells were injected into nude mice. Furthermore, expression of either antisense or dominant-negative HMGI(Y) constructs in tumor cells inhibited both their rate of proliferation and their ability to grow anchorage independently in soft agar. Analysis of the transcription profiles of cells employing cDNA arrays demonstrates that overexpression of HMGI(Y) proteins modulates the expression of a complex set of genes that are known to be involved in cell signaling, proliferation, tumor initiation, invasion, migration, induction of angiogenesis, and colonization. Importantly, immunohistochemical analyses of tumors formed in nude mice by cells overexpressing HMGI(Y) suggest that they have undergone an epithelial-mesenchymal transition (EMT) in vivo, an event consistent with the results obtained from gene transcription array analyses. These data represent direct experimental support for the hypothesis that overexpression of the HMGI(Y) proteins is causally associated with neoplastic transformation, metastatic progression, and mesenchymal transition of human breast epithelial cells in the context of an intact living organism.
MATERIALS AND METHODS
Cell culture and selection of transgenic clones. The human breast epithelial cell line MCF-7 (catalog no. HTB-22) was obtained from the American Type Culture Collection (ATCC; Manassas, Va.) and was grown in Dulbecoco's modified Eagle's medium (DMEM) supplemented with 2 mM L-glutamine, 10 mM HEPES, 10% fetal calf serum (FCS), penicillin G sodium at 100 U/ml, and streptomycin sulfate at 100 g/ml and maintained as recommended by the supplier. MCF-7/PKC␣ cells (a generous gift of D. K. Ways, East Carolina University School of Medicine [128] were grown in the same medium as MCF-7 cells but supplemented with G418 at 100 g/ml. The human epithelial cell lines Hs578Bst (ATCC catalog no. HTB-125) and Hs578T (ATCC catalog no. HTB-126), as well as the human HeLa cervical carcinoma cell line (ATCC catalog no. CCL-2), were also obtained from the ATCC and maintained as recommended by the supplier. The tetracycline-regulated M/tet, M/tet/Vec, M/tet/HA-I, and M/tet/HA-Y human breast epithelial cells were obtained as follows. The parental M/tet (MCF-7/Tet-off) cell line was purchased from Clontech, Palo Alto, Calif. (catalog no. C30071, lot no. 7080502). The M/Tet cell line was derived by stable transfection of MCF-7 cells with a tetracycline-controlled transgene coding for the tetracycline transactivator protein and exhibits normal slow-growth characteristics, is contact inhibited, and does not form tumors when injected into nude mice. The cell lines designated M/tet/HA-I or M/tet/HA-Y (e.g., M/tet/HA-IC7, M/tet/HA-YC21, etc.) are clonal derivatives of M/tet cells that have been stably transfected with a plasmid vector (Clontech) containing the tetracycline response element (pTRE) driving the expression of either a hemagglutinin (HA)-tagged HMG-I or HA-tagged HMG-Y cDNA transgene (69) . The control M/tet/Vect cells are clonal derivatives of M/tet cells that have been stably transfected with the empty pTRE vector without any insert. M/tet cells were cultured in DMEM containing 10% FCS (tetracycline free), 2 mM L-glutamine, G418 at 100 g/ml (for maintenance of selection of the gene for the tetracycline transactivator protein), penicillin G sodium at 100 U/ml, and streptomycin sulfate at 100 g/ml. Selection and maintenance of the M/tet/Vect, M/tet/HA-I, and M/tet/HA-Y cell clones were done with the same medium used for the M/tet cells, except that it contained either hygromycin at 100 g/ml for M/tet/Vect and M/tet/HA-I cells or zeocin at 50 g/ml for M/tet/HA-Y cells. In addition, the M/tet/HA-I and M/tet/ HA-Y clones were routinely maintained in tetracycline at 2 to 10 g/ml (depending on the individual clone) to keep expression of the HA-I and HA-Y transgenes turned off.
Construction and use of HMGI(Y) plasmid expression vectors. Wild-type HMG-I and wild-type HMG-Y plasmid expression vectors were created by subcloning the PCR products of the coding regions of human HMG-I and HMG-Y cDNAs (69) into the pcDNA3.1/Zeoϩ plasmid expression vector (Invitrogen) between the HindIII and BamHI sites of the polylinker. The construc-tion and use of both the antisense expression vector pRcCMVIGMH (57, 99) and the dominant-negative expression vector HMG-I (cytomegalovirusHMGImII,mIII) (58) have been described previously. HA-tagged HMG-I and HA-tagged HMG-Y expression vectors were created by fusing a synthetic DNA oligonucleotide encoding the peptide MYPYDVPDYASL from the influenza virus HA protein (i.e., HA tag) in frame to the N-terminal end of the HMG-I and HMG-Y cDNAs by standard PCR protocols (3). The PCR fragments containing either HA-tagged HMG-I or HA-tagged HMG-Y were then subcloned into the pTRE expression vector, and the sequences of the resulting expression constructs were confirmed by automated DNA sequencing prior to use.
Cell transfection and clone selection. Plasmid expression vectors were introduced into cells by employing either the DMRIE-C, the Lipofectamine, or the Lipofectamine Plus transfection reagent following the manufacturer's (Gibco BRL, Gaithersburg, Md.) instructions. Transfection efficiencies in transienttransfection experiments using antisense and dominant-negative HMGI(Y) expression vector constructs were routinely monitored by cotransfection of a cytomegalovirus-based plasmid vector expressing green fluorescent protein (GFP) at a DNA ratio of 1:1. The total viable cells and viable GFP-expressing cells were counted using a UV microscope. The percentage of GFP-expressing cells was then obtained and served as an estimate of the transfection efficiency. In many experiments, transfection efficiencies were also monitored by cotransfection of cells with a luciferase reporter plasmid and determination of luminescence activity in cell lysates using a luciferase assay kit (catalog no. E4030; Promega, Madison, Wis.) and a Top Count Luminometer (Packard Instruments).
Cell proliferation assays. Cells were trypsinized and suspended in DMEM with 10% FCS and counted using either a Coulter Counter (Coulter Corp., Hialeah, Fla.) or a hemacytometer. Cell viability was assessed using trypan blue exclusion (to obtain the percentage of viable cells). For growth curve determinations, 2 ϫ 10 4 or 4 ϫ 10 4 viable cells were initially seeded in 2 ml of medium per 35-mm diameter dish. In all experiment, cells in four or more separate culture dishes were counted on each day of a time course study in order to ensure statistical accuracy of the growth curves.
Acid extraction and Western blot analysis of total cellular HMGI(Y) proteins. Acid extraction of HMG proteins from cells with 5% perchloric acid was performed as previously described (99) . The acid-soluble proteins, which include not only HMGI(Y) but the other HMG proteins and histone H1 as well, were electrophoretically separated on either a 4 to 20% gradient or a sodium dodecyl sulfate (SDS)-15 or 18% polyacrylamide gel electrophoresis (PAGE) minigel and then transferred to an Immobilon-P membrane (Millipore) by electrotransfer overnight. Immunodetection of the HMG-I (Y) proteins on the membrane was performed using a rabbit polyclonal anti-HMG-I antibody (MR-19) whose production and use have been described previously (99) and an enhancedchemiluminescence detection procedure using the SuperSignal substrate supplied by Pierce Chemical Co., Rockford, Ill.
Immunoprecipitation and Western blot assays of HA-tagged proteins. After washing with phosphate-buffered saline, cells were directly lysed in their culture dishes (about 5 ϫ 10 6 cells/dish) by addition of 1 ml of radioimmunoprecipitation assay buffer (1ϫ phosphate-buffered saline, 1% Nonidet P-40, 00.5% sodium deoxycholate, 0.1% SDS, phenylmethylsulfonyl fluoride and aprotinin [Sigma catalog no. A6279] at 30 g/ml each, and sodium orthovanadate at 10 l/ml). The lysate was passed through a 21-gauge needle to shear the DNA and incubated on ice for 60 min. Particulates were removed from the lysate by centrifugtion at 15,000 ϫ g for 20 min at 4°C, and the supernatant containing the total soluble cellular proteins was collected. Approximately 50 l of anti-HA tag mouse monoclonal antibody (12CA5; a generous gift of J. J. Chen [16] ) was added to 100 l of lysate, and the mixture was incubated on ice for 1 h. Protein A-agarose beads (50 l; Sigma) were then added, and the mixture was incubated overnight at 4°C while rotating. The beads were collected by centrifugation, and the bound proteins were removed by washing the beads three times with radioimmunoprecipitation assay buffer. An equal volume of SDS-PAGE sample buffer was added to the eluate, and the mixture was boiled for 2 min. The proteins in the eluate were separated by electrophoresis on an SDS-15% PAGE minigel and then transferred to a nitrocellulose membrane using a semidry electrophoretic transfer cell (Trans-Blot SD; Bio-Rad). The enhanced-chemiluminescence detection procedure described above was then used to identify the membrane-bound, HA-tagged proteins.
Soft agar anchorage-independent growth assays. Seven milliliters of molten 0.6% Difco agar (44°C) in DMEM with 10% FCS and the desired antibiotic (such as G418, tetracycline, hygromycin, or zeocin, etc.) was poured into 60-mm diameter petri dishes and allowed to solidify for 30 min. The desired numbers of cells and the desired antibiotics were then layered over the hardened agar in 1.5 ml of molten (44°C) 0.33% low melting temperature Difco agar containing DMEM and 10% FCS, and the dishes were allowed to sit for 10 min before transfer to an incubator. Cultures were incubated at 37°C in 5% CO 2 with over 90% humidity for about 30 days. The colonies were stained using a 0.25-mg/ml solution of [2-(p-iodophenyl)-3-␥(p-nitropheyl)-5-phenyl tetrazolium chloride (Sigma) for 6 to 24 h at 37°C in a 5% CO 2 incubator. Colonies containing more than 50 cells were visually counted.
Analysis of gene expression profiles using cDNA arrays and quantitative RT-PCR. The commercial Atlas Human Cancer cDNA Expression Array kit (catalog no. 7742-1) supplied by Clontech was used to establish gene expression array profiles. The isolation of total cellular RNA, the preparation of cDNA probes, and the hybridization of the cDNA array membranes followed the protocols supplied by the manufacturer (Clontech manual PT3140-1, version PR89832). Following hybridization, the membranes were exposed to a PhosphorImager screen, the screen was developed, and the resulting hybridization images were analyzed and quantitatively assessed using ImageQuant software (Molecular Dynamics, Inc.).
Standard protocols for quantitative reverse transcriptase PCR (RT-PCR; 63) were used to evaluate the levels of specific gene transcripts in cells. Total cellular RNA was isolated using Trizol reagent (Life Technologies, GIBCO; catalog no. 15596) following the instructions of the manufacturer. A mixture of 1 g of RNA and 20 M primer poly(T 25 ) oligonucleotides (Collaborative Research) was reverse transcribed with 10 U of Moloney murine leukemia virus reverse transcriptase (Promega Corp.) in a PCR thermal cycler at 42°C for 60 min to produce cDNA, and the mixture was then heat denatured and cooled. Diluted samples of this cDNA were then mixed with two different PCR primer pairs, one that is specific for the gene transcript of interest and a second that is specific for a constitutively synthesized message that acts as an internal reference standard (e.g., hypoxanthine-guanine phosphoribosyltransferase [HPRT] ) for the amplification reaction. The mixture was then PCR amplified in a thermal cycler for 25 cycles of 95°C for 1 min, 60°C for 1 min, and 72°C for 1 min. The resulting RT-PCR products were separated by either electrophoresis on a native agarose gel or non-denaturing PAGE and detected and quantified by PhosphorImager analysis.
Nude mouse tumor formation assays. Female BALB/c (nu/nu) mice 4 to 6 weeks old were purchased from The Jackson Laboratory, Bar Harbor, Maine. For tumor formation assays, approximately 5 ϫ 10 6 M/tet/Vect cells, HA-HMG-I-expressing cells, or HA-HMG-Y-expressing cells in serum-free medium were injected into either the mammary fat pad or the subcutaneous space under the skin of the nude mice. The mice were maintained in a germfree facility, and tumor incidence and size were observed at regular intervals and documented.
Histology and immunohistochemistry. Tumor nodules were fixed in 10% formalin and embedded in paraffin, and 4-to 6-m sections were mounted onto slides and stained with hematoxylin and eosin by the histochemistry core facility of the Center for Reproductive Biology, Washington State University. Immunostaining of tissue sections that had been preserved in Histochoice fixative (Sigma) followed standard protocols. Antigen retrieval for vimentin detection was done by microwave heating in citrate buffer. Before adding horseradish peroxidaseconjugated reagents, endogenous peroxidase activity was blocked by a methanol-H 2 O 2 solution. For immunolocalization studies, tissue sections were reacted with a primary antibody (either a monoclonal mouse antibody or a polyclonal rabbit antibody), washed, and then reacted with either biotinylated goat anti-mouse immunoglobulin G (IgG; Vector Laboratories; 1:200) or biotinylated goat antirabbit IgG (Bio-Rad; 1:1,000). Biotinylated antibodies were visualized by reaction with horseradish peroxidase-streptavidin reagent (Vector Laboratories) and diaminobenzidine staining, followed by counter staining of nuclei with Meyer's hematoxylin. The antibodies and dilutions used for tumor immunostaining were anti-HA tag mouse monoclonal antibody 12CA5 (1:50 dilution), anti-pan-cytokeratin (C11) mouse monoclonal antibody (1:50 dilution; Santa Cruz Biotechnology), and anti-vimentin (V9) mouse monoclonal antibody (1:50 dilution; Santa Cruz Biotechnology). Both the mouse monoclonal anti-human procollagen alpha type I antibody M-38 (1:50 dilution; developed by J. A. McDonald) and the mouse monoclonal anti-procollagen alpha type III antibody SP1.D8 (1:50 dilution; developed by H. Furthmayr) were obtained from the Developmental Studies Hybridoma Bank, a contract facility supported by the National Institute of Child Health and Human Development and maintained by the Department of Biological Sciences, University of Iowa, Iowa City. Rabbit polyclonal antibody 8691 (1:40 dilution), a general anti-human alpha 1 (XI) collagen antibody, and rabbit polyclonal antibody 1703 (1:40 dilution), specific for the v2 and vlav2 isoforms of human alpha 1 (XI) collagen associated with mesenchymal and not cartilaginous tissues, were both generous gifts from Julia Oxford, Oregon Health Sciences University.
RESULTS
Endogenous HMGI(Y) protein levels correlate with the tumorigenic potential of human mammary epithelial cells. In preliminary experiments, a number of different normal and malignant human breast epithelial cell types were examined for both the levels of endogenous HMGI(Y) proteins and the ability to respond to artificial manipulation of these levels by the introduction of antisense or dominant-negative HMGI(Y) expression vectors. Among those tested were two matched pairs of human mammary epithelial cell lines (lines Hs578Bst and Hs578T and lines MCF-7 and MCF-7/PKC␣). Each pair was originally derived from the same parent, but the individually lines exhibit markedly different tumorigenic phenotypes. The aneuploid Hs578T cell line originated from a human mammary epithelial carcinoma (46) and grows aggressively in soft agar, exhibits invasive properties in in vitro matrigel outgrowth assays, and causes tumors that extensively metastasize in immunodeficient nude mice (111) . In contrast, the diploid Hs578Bst cell line is a nontumorigenic myoepithelial cell line established from normal breast tissue of the same patient (46) but, unlike Hs578T, does not grow in soft agar, is not invasive in matrigel assays, and does not cause tumors in nude mice. The human MCF-7 breast epithelial cell line is estrogen receptor positive and retains many of the biochemical and phenotypic characteristics of normal mammary epithelial cells (76) . It has only a very limited ability to grow in soft agar (128) , is noninvasive in matrigel assays, and does not form tumors in nude mice (111, 128) . On the other hand, the MCF-7/PKC␣ cell line is a derivative of MCF-7 cells that has been stably transformed with a transgenic cDNA that codes for the transforming oncogene protein kinase C␣ (PKC␣). This PKC␣-over expressing cell line readily growns in soft agar in vitro, is invasive in matrigel assays, and readily produces aggressive tumors that metastasize when injected into nude mice (128) . (99) . Also shown as a positive control on this blot are the amounts of endogenous HMGI(Y) proteins found in the malignant HeLa cervical adenocarcinoma cell line (lane 1), which is known to contain high levels of these proteins (81) . Figure 1B shows a Commassie blue-stained gel of the H1 proteins present in the same protein samples used for the immunoblot in panel A that served as an internal standard for total protein loading on the gels. From Fig. 1 , it is evident that the amount of endogenous HMGI(Y) proteins present in these mammary epithelial cell lines closely correlates with their degree of in vivo tumorigenicity, a finding consistent with many previous studies (14, 116) . Specifically, the nontumorigenic Hs578 and MCF-7 cell lines contain low or nondetectable levels of endogenous HMGI(Y) proteins whereas these proteins are exceedingly abundant in the highly malignant Hs578T, MCF-7/PKC␣, and HeLa cell lines.
Antisense HMGI(Y) expression inhibits cell proliferation and anchorage-independent growth. To further explore the role of HMGI(Y) in tumorigenesis, transfection experiments were performed in order to modulate the amounts of these proteins in various epithelial cell lines in order to determine whether there is a mechanistic connection between the endogenous level of HMGI(Y) proteins and cell proliferation rates or other phenotypic characteristics. Previous studies have demonstrated that the endogenous levels of HMGI(Y) proteins can be dramatically reduced in cells by the introduction of antisense expression vectors (8, 102) and that both antisense and dominant-negative expression vectors can significantly inhibit the in vivo transcription of genes regulated by the HMGI (Y) proteins (57, 58, 121) . Figure 2 shows the results of experiments in which either the antisense pRcCMVIGMH (57) vector or, as a control, the empty parental pRcCMV vector without any insert was individually transfected into MCF-7, Hs578T, and HeLa cells. The transfectants were selected with G418 for a week, and pools of the G418-resistant cells from each cell line were then subcultured and their relative growth rates were determined by cell counting. As is evident from that it is unable to reduce the very high concentrations of endogenous HMGI(Y) proteins found in HeLa cells to a level that would slow cell proliferation. Nevertheless, these transfection results clearly indicate that antisense HMGI(Y) expression impacts the growth rate of cells with low-to-moderate levels of endogenous HMGI(Y) proteins. Additional transfection experiments also demonstrated that antisense expression inhibited the anchorage-independent growth of some lines of mammary epithelial tumor cells in soft agar (data not shown). Taken together, the results from these two independent lines of antisense experiments indicate that reduction of endogenous HMG-I(Y) levels in cells can lead to a decrease in their proliferation rates and a reduction of the ability of some tumor cells to grow anchorage independently.
Overexpression of exogenous HMGI(Y) proteins promotes anchorage-independent growth in soft agar. A series of preliminary transfection experiments demonstrated that transfection of MCF-7 cells with a wild-type HMG-I or HMG-Y vector whose transcriptional expression was driven by a highly efficient constitutive promoter resulted in a marked increase in the total amount of HMGI(Y) proteins in the recipient cells and also resulted in a significant increase in their ability to grow anchorage independently in soft agar (data not shown). There is, however, an intrinsic problem that interferes with an unambiguous interpretation of these and other, similar studies (37, 94, 132) . Namely, owing to the fact that HMGI(Y) proteins can influence the transcriptional activity of the host cell's endogenous Hmgiy gene promoter (unpublished observations), it is difficult, if not impossible, to distinguish between the amount of HMGI(Y) proteins in the transfected cells contributed by expression of the introduced transgene and the amount of these proteins contributed by expression of the endogenous host cell gene.
To circumvent the problem of protein identification, plasmid expression vectors were constructed that produced either HMG-I or HMG-Y proteins containing a nine-amino-acid peptide derived from the HA protein of influenza virus fused to their N-terminal ends. Furthermore, these transgenes were under the transcriptional control of a tetracycline-regulated promoter element (30) and were transfected into a genetically engineered MCF-7 cell line that synthesizes the Tet regulatory protein, whose activity was controlled by the presence or absence of tetracycline in the cell culture medium. Specifically, in the Tet-off expression system employed, genetically engineered MCF-7 cells that were stably transfected with either the HAtagged HMG-I or HMG-Y gene produced large amounts of the corresponding HA-tagged protein in the absence of tetracycline in the culture medium. In contrast, when tetracycline was added to the cell culture medium, production of the HAtagged transgenic protein was shut off. Thus, by using this tetracycline-regulated gene transcription system, the expression of either the HA-HMG-I or HA-HMG-Y transgenic protein in MCF-7 cells could be reversibly controlled at will and the resulting levels of protein expression could be quantitatively assessed. A major advantage of using HA-tagged pro- teins is that the exogenous HMG-I(Y) proteins can be easily distinguished from the endogenous proteins in transgenic cells by means of a monoclonal antibody (12CA5) directed specifically against the HA tag peptide that was used for immunoprecipitation of HA-tagged proteins during screening for clones expressing high levels of exogenous HMGI(Y) proteins (30) . As shown in Fig. 3 , by using immunoprecipitation and Western blotting analysis, several independently derived transgenic MCF-7 clones that express high levels of either HA-HMG-I or HA-HMG-Y protein were identified. In these experiments, the HA-HMGI(Y) proteins were first immunoprecipitated from the transgenic clones by using the 12CA5 antibody and then the HMG-I and HMG-Y proteins in the immunoprecipitates were identified by Western blotting using the MR-18 antibody directed against wild-type HMGI (Y) proteins. As is evident in Fig. 3 , all of the clonal MCF-7 cell lines containing the HA-tagged HMG-I (i.e., HA-I-Cs, HA-I-C7, and HA-I-C14) or HMG-Y gene produced high concentrations of the respective HA-tagged transgenic protein when the gene was transcriptionally on (i.e., in the absence of tetracycline). In contrast, expression of either the HA-HMG-I or HA-HMG-Y transgenic protein could be completely inhibited (i.e., turned off) in these transgenic cells by the addition of 2 to 10 g of tetracycline (depending on the clone) to the cell culture medium, with the exception of clone of HA-I-C7, which required higher levels of the drug to be completely repressed (data not shown). Importantly, control Western blot experiments in which total acid-soluble proteins isolated from the on cells were run under electrophoretic conditions that separated the HMG-I from the HMG-Y isoform protein also demonstrated high-level expression of the HA-tagged transgenic proteins in the on transfected cells when an anti-HMGI (Y) antibody was used as a probe (data not shown).
To test the effects of expression of the exogenous HMG-I or HMG-Y protein, MCF-7 clones producing these transgenic proteins were tested in the soft agar assay for the ability to exhibit anchorage-independent growth. Figure 4 shows a typical example of cells containing the exogenous HMG-I or HMG-Y-encoding gene growing in soft agar with (expression off) or without (expression on) tetracycline treatment. As summarized in Table 1 , the HMG-Y-expressing clones HA-Y-C10, HA-Y-C19, and HA-Y-C21 produced, depending on the clone, 13-to 39-fold more colonies in soft agar when the gene is on than when it is off. Similarly, HMG-I-expressing clones HA-I-C14 and HA-I-Cs formed about 10-to 20-fold more colonies. We therefore conclude from these experiments that overexpression of either the HMG-I or HMG-Y isoform protein in MCF-7 cells induces reproducible changes in the phenotype of these cells, including an ability to exhibit anchorageindependent growth in soft agar.
Array and RT-PCR analyses of gene transcription profiles in cells overexpressing HMG-I and HMG-Y.
To identify the tumor-promoting genes that are altered by HMG-I and HMG-Y overexpression in vivo, Atlas Human Cancer cDNA Expression Arrays (Clontech Inc.) were used to generate tumor gene expression profiles. The array was a carefully selected collection of cDNA fragments arranged on nylon membranes for rapid assessment of the differential gene expression of 588 tumor-associated genes. These well-characterized genes broadly represented many crucial cellular signaling pathways and other complex biological functions that have been associated at the molecular level with changes underlying tumor progression and metastasis.
Using these arrays, gene transcription expression profiles were compared in two clonal transgenic cell lines, HA-Y-C21 and HA-I-C7, which, as shown in Fig. 3 , express high levels of HA-tagged HMG-Y and HA-tagged HMG-I proteins, respectively, when on. For each of these experiments, total RNA was isolated from both control (i.e., off) cells not expressing transgenic proteins and from cells expressing high levels of HAtagged protein (i.e., on) and reverse transcribed into cDNA with 32 P labeling. The two cDNA probe populations were then separately hybridized with two identical Atlas Array nylon membranes on which the 588 genes were spotted in duplicate. The membranes were then developed by exposure to a phosphorimaging screen, and the expression profiles of the two RNA populations were compared side by side, as shown in the representative result for HA-HMG-Y-OFF and HA-HMG-Y-ON profiles in Fig. 5 . Similar hybridization profiles were generated for HA-HMG-I-OFF and HA-HMG-I-ON clones (data not shown).
The intensity of each of the hybridizing spots on the membrane was quantified by PhosphorImager analysis using six housekeeping genes placed on each array membrane in order to normalize the hybridization signals. These housekeeping genes (which generated nearly equal-intensity hybridization signals for all of the samples being compared) were those for HPRT, ubiquitin, ribosomal protein S9, 23-kDa highly basic protein, beta-actin, and phospholipase A2. In addition, the hybridization signals of cDNAs surrounding a specific target cDNA were used both as references for normalization and for confirmation of relative intensities.
The criterion we chose for identifying the most important differentially regulated genes is that their expression had to be altered fourfold or more compared to other populations of mRNAs. A 4-fold difference as a standard is quiet stringent considering that many other studies using gene array analyses have considered 1.4-to 3-fold differences in expression to be biologically significant (2, 34, 64, 92) . Furthermore, this degree of difference in transcriptional expression can be easily detected and independently confirmed by quantitative RT-PCR techniques (see below). Table 2 The 85 genes whose transcriptional expression was significantly altered in response to overexpression of HMG-Y protein were distributed in all 13 categories. However, as shown in Fig. 7 , the patterns of alteration of gene expression were found to be quite different within the various individual categories. For example, in category H (i.e., cell adhesion, motility, and invasion genes) and category J (i.e., invasion regulators), expression of ϳ24% (20 of 82) and ϳ21% (8 of 39) of the genes, respectively, were significantly altered and all were upregulated. In marked contrast, in category E (i.e., DNA damage response, repair, and recombination genes), alteration of the expression of only ϳ9% (3 of 33) of the genes was observed and all of these were downregulated. It may be argued that the grouping and classification of the cDNA clones of the Atlas Array (as suggested by the manufacturer) are in some ways artificial and/or arbitrary; nevertheless, the observed expression pattern variations provide strong evidence that overexpression of the HMGI(Y) proteins differentially regulates, either directly or indirectly, the transcriptional activity of various categories of genes in vivo.
Overexpression of HMG-Y promotes tumor formation and metastasis in nude mice. The tumorigenicity and metastatic In marked contrast, when HA-HMG-Y-expressing cells were inoculated directly into mammary fat pats, not only were primary tumors formed at the site of injection but numerous secondary tumors were found to have metastasized into most of the mesenchymal tissues of the abdominal cavity, as well as into the connective tissues surrounding and supporting various organs (Fig. 8A to C) . The sites of metastasis included the mesentery supporting the large and small intestines and the colon, the greater omentum, the mesentery lining of the diaphragm, and the fibrous capsule around the kidneys. Histological examination revealed that these secondary metastatic tumors were often collagen-rich carcinomas that showed a complex, pleiomorphic cytology with different regions of the tumors exhibiting markedly different morphological characteristics (Fig. 9 ). Some areas of the metastatic carcinomas exhibited a compact, more-or-less epithelial cell-like, cobblestone morphology ( Fig. 9A and B) , whereas other areas were more loosely organized and often surrounded by, or infiltrated with, collagen fibers (Fig. 9C) . In some cases, the metastatic tumors were not confined to the mesentery and fibrous connective tissues but exhibited considerable anaplasia with invasion of underlying organ stroma structures, such as the striated muscle tissue of the diaphragm (Fig. 9B) . Importantly, the presence of blood vessels within or near masses of tumor tissue was commonly observed (e.g., Fig. 9A and B) , suggesting that the tumor cells had induced angiogenesis and/or that they had extravasated from nearby blood vessel during their migration and metastasis.
Another commonly observed feature in many of the HMG-Y-induced metastatic tumors was the presence of areas of less organized, more elongated cells with variant morphologies that contained appreciable concentrations of extracellular collagen. For example, as shown in Fig. 9C , islands of epithelioid carcinoma cells with little apparent collagen were often observed adjacent to nearby areas of more elongated and spindleshaped tumor cells surrounded by a dense, collagen-rich matrix. Nevertheless, as illustrated in Fig. 9D to F, perhaps the most interesting and potentially significant feature observed in the metastatic tumors was the presence of localized areas of less differentiated cells that seemed to possess an unorganized, carcinosarcoma-like morphology (38) . These results suggest that some of the metastatic tumor cells have undergone a phenotypic change from their original epithelial cell-like phenotype to a more mesenchymal cell-like phenotype as a consequence of overexpression of the HMG-Y protein. Such phenotypic changes require extensive alterations in gene expression patterns and are called EMTs (51) . The phenomenon of EMT is a common feature of both embryonic development (123) and advanced epithelial tumors where epithelial cells have dedifferentiated to a more fibroblast-like state and regained the ability to invade, migrate, and/or proliferate in an (9) . The EMT of epithelial tumors is characterized by a number of phenotypic changes, including loss of cell-to-cell interactions; the acquisition of a more fibroblast-like cellular morphology, the downregulation of epithelial cell products such as cytokeratins, the upregulation of mesenchymal cell marker proteins such as vimentin, a marked increase in the production of cytoplasmic procollagen and extracellular collagen fibers, and the acquisition of a motility machinery that allows cells to interact in three dimensions with the extracellular matrix (ECM) (9, 10) . HMG-Y overexpression induces EMT in tumor cells. Immunohistochemical staining of tumor sections was performed using a number of monoclonal and polyclonal antibodies directed against specific proteins to confirm that the tumors formed in nude mice had, indeed, originated from the transgenic MCF-7 cells and to further investigate the possibility that these cells had undergone an EMT. The antibodies used for these studies were selected on the basis of the gene products indicated by cDNA array analysis to be produced in the transgenic cells (Table 2 ) and on the basis of the histological appearance of the tumors themselves (Fig. 9A to F) . For example, reaction of tumor sections with a monoclonal antibody directed against the HA tag peptide show that the transgenic human HMG-Y protein was localized primarily in the nuclei (but with detectable cytoplasmic staining) of cells in both regions of carcinoma morphology (Fig. 9H) and regions of carcinosarcoma morphology (Fig. 9I) . These results unambiguously demonstrate that the tumors originated from the injected human MCF-7 cells overexpressing the HMG-Y protein, a fact also confirmed by the ability to reisolate tetracycline-regulated transgenic cell lines from the tumors by growth in selective medium (data not shown).
The list of genes differentially regulated by HMG-Y shown in Table 2 indicates that a number of types of collagen proteins, especially pro-alpha I-type collagens, are dramatically upregulated in the HMG-Y-overexpressing transgenic cells. This finding is confirmed by the immunoreactive staining of the cytoplasm of tumor cells with a peptide monoclonal antibody that is specific for human fibroblast pro-alpha I-type collagen and does not cross-react with mouse proteins (Fig. 9J) . Likewise, a polyclonal rabbit antibody directed against the isoforms of human alpha I (XI) collagen that are associated with mesenchymal and noncartilaginous tissues stains the extensive extracellular collagen accumulations found in tumor tissues, indicating that the tumor cells are synthesizing and secreting these proteins (Fig. 9K) . These findings are significant because excess collagen production is a characteristic feature of EMT. High levels of type I and type III procollagen proteins are also observed in the most aggressive human breast cancers, with the level of collagen expression being positively correlated with the degree of malignancy of the tumor (12, 71) . The cDNA array analyses also indicated that expression of the gene coding for the classical mesenchymal cell marker protein vimentin, a diagnostic protein for EMT, is significantly upregulated (ϳ5.6-fold) in transgenic cells. This expression is confirmed by the reaction of tumor tissue with a monoclonal antibody that is specific for human vimentin and does not cross-react with other human intermediate filament proteins, with mouse vimentin, or with other murine proteins (Fig. 9L) . Finally, a pancytokeratin monoclonal antibody against human proteins that does not cross-react with mouse cytokeratins also stains the cytoplasm of tumor cells, consistent with the array analyses ( Table 2 ) that indicated that cytokeratins 10 and 12 are upregulated in the transgenic cells (data not shown). Although cytokeratins are usually thought of as epithelial cell differentiation markers, the most aggressive human breast cancers that have undergone EMT coexpress both vimentin and cytokeratins (28, 109) , as do some malignant mouse mammary epithelial tumors that have undergone in EMT (113) . Together, these immunostaining results not only demonstrate the transgenic human cell origin of the tumors formed in nude mice but are also entirely consistent with previous results indicating that some of the HMG-Y-overexpressing cells having undergone an EMT.
DISCUSSION

HMGI(Y) proteins are causal agents in tumor progression.
As recounted in the introduction, published reports of human clinical studies, as well as numerous studies of animal and cell culture model systems, have firmly established that aberrant expression or overexpression of members of the HMGI(Y) gene family positively correlates with neoplastic transformation and metastatic progression of a wide variety of tumors. Nevertheless, the results reported here represent the first direct demonstration that overexpression of the HMGI(Y) proteins is causally involved in modulating the expression of genes involved in all stages of tumor progression from transformation to anchorage-independent growth in vitro, to the formation of primary and metastatic tumors in nude mice, and the induction of in EMT in vivo. The current data unambiguously confirm the long-held suspicion the Hmgiy is a bone fide protooncogene and also provide insights into probable molecular events underlying its in vivo mode of action.
The results of gene array analyses revealed that induced overexpression of HMGI(Y) proteins in human mammary epithelial cells modulated, either upward or downward, the transcriptional expression of constellations of genes associated with regulation of cell signaling, cell proliferation, cell migration, tissue invasion, induction of angiogenesis, and metastatic (Table 2 ; Fig. 7 ). Whether the HMGI(Y) proteins function directly as transcription factors by regulating the promoters of these genes or whether their effect is indirect and is mediated through other intermediary genes or proteins is unknown. Nevertheless, it is quite remarkable how closely the cDNA expression array profiles induced by HMGI(Y) overexpression correspond to the phenotypic patterns of the metastatic tumors formed by transgenic cells injected into nude mice. Examination of the pathology in host mice clearly showed that the HMG-Y transgene-containing cells injected into the mammary fat pad had metastasized to many distant sites in the mesenteries lining the body cavity and various organs and had also invaded muscle tissues, such as the diaphragm (Fig. 8 A to C) . These biological results could only be achieved if many of the tumor progression gene products detected by the cDNA array analyses were indeed functional in vivo, a conclusion also supported by the histochemical and immunolocalization results shown in Fig. 9 .
In vivo, the HMG-I and HMG-Y isoform proteins are not functionally equivalent. One of the most unexpected findings in this study was that transgenic cells overexpressing the HMG-Y isoform protein were much more effective in inducing both primary and metastatic tumors when injected into nude mice than were transgenic cells overexpressing the HMG-I isoform protein (Table 3 ). In less than 2 months following injection, over half (four of seven) of the nude mice injected with cells overexpressing the HMG-Y protein had developed tumors whereas during this same time period none of the five mice injected with cells overexpressing HMG-I developed tumors. Only much later (after about 4 months) did one of the mice injected with cells overexpressing the HMG-I protein develop small primary tumors (data not shown). Thus, HMG-Y is far more efficient in promoting tumor progression in vivo than HMG-I even though these isoform proteins differ only by an internal deletion of 11 amino acids in the former. These results were initially puzzling, since expression of both isoform proteins efficiently induced anchorage-independent growth in soft agar ( Fig. 4; Table 1 ). Nevertheless, they were consistent with an earlier report demonstating that the tumor promoter 12-O-tetradecanoylphorbol acetate preferentially induces HMG-Y protein expression in transformation-sensitive, but not in transformation-resistant, mouse JB6 epithelial cells in culture (22) . The cumulative data therefore strongly imply that, in addition to sharing many common biological functions, the HMG-I and HMG-Y proteins also exhibit important differences in their in vivo functions. This view is further supported by the finding that in vivo, the HMG-Y protein contains many more secondary biochemical modifications than the HMG-I isoform and that these modifications differentially affect the substrate-binding properties of the two proteins (5). A potential difference in function between the two isoforms is likewise supported by the results of the cDNA expression profiles and RT-PCR experiments reported earlier ( Fig. 5 and 6 ; Table 2 ). The data from these experiments demonstrate that the HMG-I and HMG-Y proteins do, indeed, regulate the transcriptional expression of a large constellation of common genes but also indicate that, in addition, each protein can regulate its own independent set of genes. For example, both proteins upregulate the expression of genes such as those which encode the p38 mitogen-activated protein kinase (MAPK), collagen type XVIII, integrin ␤1, MMP13, and TIMP (tissue inhibitor of MMP3), but on the other hand, only HMG-Y upregulates genes such as those for Notch-4, Jagged-1, and Wnt-10B (Fig. 6 ) and only HMG-I downregulates the genes for Wnt-10B and Wnt-8B (data not shown). It is reasonable to suspect that the constellation of genes regulated by both the HMG-I and HMG-Y proteins is responsible for the anchorage-independent growth in soft agar of cells overexpressing these proteins. On the other hand, it is likely that some combination of the individual genes that are either up-or downregulated by the HMG-Y or HMG-I isoform protein is responsible for the much greater in vivo tumorigenic and metastatic potential of the HMG-Y protein. It should be stressed that the cDNA array analyses reported here sampled the transcriptional activity of only a very limited number of cellular genes. To fully address the issue of the extent to which the HMG-I and HMG-Y isoform proteins have distinct biological functions in tumor progression, a much more comprehensive transcriptional expression analysis employing highdensity oligonucleotide array technology is necessary.
Genes modulated by HMGI(Y) overexpression. The list of genes differentially regulated by HMG-Y overexpression in Table 2 demonstrates a broad range of functional activity of the HMG-Y architectural transcription factor. During mouse development, very high expression of HMGI(Y) proteins has been detected in all embryonic tissues up to 8.5 days of gestation, a period during which the most critical events of organogenesis start to take place, and its expression continues at lower levels to the end of gestation (17, 78) . Based on these patterns of embryonic expression, the suggestion has been made that the HMGI(Y) proteins are not only involved with cell proliferation but also are likely to be involved with the establishment of various cell types during organogenesis. This suggestion is supported by the present data, which demonstrate that overexpression of HMG-Y significantly upregulates genes known to be involved in development, such as those for Frizzled 5 (161-fold), Wnt-13 (14.6-fold), Wnt-10B (4.1-fold), as well as Jagged-1 and its receptor, Notch-4 (7.5-and 4.1-fold, respectively). HMG-Y also upregulates a number of genes involved in both cell cycle regulation and signal transduction. These include the genes for CLK-1 (14.6-fold), cdc25A (98.6-fold), cdc25B (9.1-fold), cyclin C (5.1-fold), JNK2 (7.4-fold), and p38 MAPK (5.7-fold) and others. Each of these genes has been demonstrated not only to be involved in either the control of cell cycle or signaling processes but also to participate in neoplastic transformation and/or tumor progression in various systems. For example, the genes coding for the protein phosphatase enzymes cdc25A and cdc25B are well known as G 1 /S transition and G 2 /M transition regulators, respectively. In addition, they are all proto-oncogenes whose overexpression has been implicated in many types of tumors, including breast cancers (60, 135) .
HMG-Y modulates expression of EMT genes. Although studies analyzing the molecular characteristics of both mesenchymal and epithelial cells are still at an early stage, a group of genes has already been identified that is both characteristic of these two different cell types and influential in EMT (reviewed in reference 9). Analysis of the cDNA profile of epithelial cells overexpressing HMG-Y protein indicates that transcriptional expression of several EMT marker genes is modulated in HMG-Y overexpressing cells (Table 2) . Among the group of upregulated genes are type I, III, and IV collagens, vimentin, certain cytokeratins, a number of matrix metalloproteases, basic FGF receptor 1, FGF7, and SF (scatter factor-hepatocyte growth factor) protein. Amoung the group of downregulated genes are those coding for the EGF receptor and TGF-␤ receptor III, as well as those coding for both the Met and FGFR2b proteins.
As noted previously, excess collagen production is a characteristic feature of EMT and clinical studies have correlated high levels of procollagen proteins with the most aggressive human breast cancers and those with the worst prognosis (12, 71) . The cells of many of these highly malignant breast tumors also coexpress elevated levels of both vimentin and cytokeratins (29, 108, 113) .
Extracellular and membrane-bound MMPs are a family of enzymes involved in much of the degradation of ECM molecules that occurs in developmental and pathological processes, including tumor invasion and metastasis and EMTs (84, 113) . (53) . Interestingly, in these breast carcinomas, MMP13 is expressed by tumor stromal cells or fibroblast-like tumor cells (also referred to as mesenchymal cells) (53) . In addition to upregulating metalloproteases, overexpression of HMG-Y also increases the metalloprotease inhibitor TIMP-3 and plaminogen activator inhibitors PAI-1 and PAI-3 4.6-, 5.4-, and 74.2-fold, respectively. Overexpression of both TIMP-3 (125) and PAI-1 (101) has been detected in breast carcinomas, and high levels of PAI-1 are associated with a higher incidence of lymph node involvement in breast cancer and poor response to tamoxifen therapy (65) . The role of MMP-inhibitory proteins such as TIMP-3 and PAI in tumor invasion and metastasis is unresolved and controversial, but many investigator now lean toward the view that there is a delicate interplay between these inhibitory proteins and the MMPs that regulate the invasiveness of tumor cells by controlling cellular adhesion to, and release from, the ECM (27) .
SF and its specific receptor, c-Met, have been implicated in EMTs during both development (110) and tumor invasion and metastasis (9) . SF is a potent pleiotrophic cytokine with multiple biological effects on various epithelial cells, including morphogenesis, proliferation, migration, and differentiation. It promotes development, regeneration, and reconstitution of normal organ architecture. The normal physiological roles played by SF and c-Met have been established in embryological studies. In the majority of tissues, SF is expressed exclusively on mesenchymal cells and c-Met, a receptor tyrosine kinase, is expressed on epithelial cells (110) . The exchange of signals between the mesenchymal and epithelial cells has long been recognized as a major driving force in embryogenesis, and SF and c-Met constitute one such major paracrine signaling system (114) . In the development of epithelium lined organs, for (Table 2 ). This strongly suggests that, in some cases, overexpression of HMG-Y promotes an EMT by coordinately upregulating the expression of mesenchymal cells genes and downregulating the expression of epithelial cell genes.
FGF7, which is produced by fibroblastic cells, and its receptor, FGFR2b, which is found on the surface of epithelial cells, represent another example of a paracrine system that actively mediates communication between mesenchymal and epithelial cells during embryonic development (130) (62) . Many of the different ␣ and ␤ subunits come in alternatively spliced forms which are expressed in a tissue-specific manner with different cell types producing multiple, but distinctive, sets of heterodimers. Although expressed on many different cell types, integrins are expressed predominantly in the mesenchyme during embryonic development (36) .
Integrins functions as transmembrane linkers (or integrators) and mediate the interactions between the cytoskeleton, cytoplasmic kinases, and the ECM. Owing to this property, integrins enable the inside of cells and the ECM to communicate with each other across the plasma membrane in a bidirectional fashion (20, 41) . That is, the extracellular binding activity of integrins is regulated from the inside of the cell (inside-out signaling) while binding of the ECM elicits signals that are transmitted into the cell (outside-in signaling). As one of the key signaling transducers, integrins influence cell shape, movement, proliferation, development, differentiation, and death (62) . These cellular effects involve changes in the expression of many genes, including those coding for integrins themselves. Transcription factors are often the final executors of signals emanating from integrins and mediate the changes observed in gene expression patterns.
Overexpression of HMG-Y significantly upregulates the expression of several integrin genes, including those coding for the ␤1, ␤3, ␤8, ␣1, ␣6, ␣9, and ␣E proteins, as well as those coding for certain of the cellular components of integrin sig-naling pathways, such as integrin-linked kinase (ILK), protein tyrosine kinase 2 (also known as cell adhesion kinase ␤), c-Jun N-terminal kinase 2, p38 MAPK, and RhoC, a member of the Rho family of small GTP-hydrolyzing proteins (Table 2 ; Fig.  10 ). Since the cDNA array used in the present expression studies included only a restricted subset of the many genes known to be involved in integrin signaling, the data set is incomplete. Nevertheless, even with the limited amount of information available, it is clear that overexpression of HMG-Y upregulates the expression of many integrins and their signaling pathways and these, in turn, are likely to be causally involved in tumor progression.
Of particular interest is the fact that HMG-Y overexpression upregulates transcription of the integrin ␤1 gene. Integrins containing the ␤1 subunit are normally activated through binding to components of the ECM. The cytoplasmic domain of the ␤1 subunit is thought to interact directly with components of the actin cytoskeleton, such as ␣ actinin and talin, thereby forming focal adhesion plaques (49) in the cytoplasm at points of contact between integrins and the ECM. The essential nature of the integrin ␤1 protein in linking the ECM and the actin cytoskeleton was shown by gene knockout experiments which demonstrated that ␤1 integrin deficiency in mice results in inner-cell mass failure and peri-implantation lethality (112) . Elevated levels of ␤1 integrins are correlated with high proliferation potential and also serve as markers for stem cells (70, 90, 120) . Overexpression of ␤1 integrin has been detected in many types of cancers and associated with metastasis. In human breast cancer, the total ␤1 integrin level is significantly higher in malignant epithelial cells than in nontumorigenic cells (129) . By using a function-blocking antibody that inhibits ␤1 integrin, malignant breast epithelial cells have been demonstrated to undergo a striking morphological and functional normalization; moreover, these reverted cells became growth arrested and were found to exhibit reduced tumorigenicity in nude mice (129) . In ovarian carcinomas, aggregation of ␤1 integrins mediates tumor invasion and metastasis by stimulation of the expression of MMP2 and MT1 MMP (31) . The notion of ␤1 integrins promoting metastasis has been supported by other studies as well. Targeted disruption of the ␤1 integrin gene in T-cell lymphomas greatly reduces their metastatic capacity (115) . Reciprocally, re-expression of ␤1 integrin in ␤1-deficient epithelial cells led to a malignant, cell-scattering phenotype that requires activation of the Rho family of GTPases (45) . Most interestingly, small-cell lung cancer cells are apparently able to utilize ␤1 integrin to resist chemotherapeutic agents (103) . In small-cell lung cancer tumors, ␤1 integrin-mediated adhesion of cells to ECM proteins around the tumor enhances tumorigenicity and activates protein tyrosine kinase activity that inhibits the activation of caspase-3 and apoptosis that is normally induced by chemotherapeutic agents (103) .
The ␣9 protein is a recently identified integrin subunit that forms only one integrin heterodimer, the ␣9␤1 integrin (90) . Expression of ␣9␤1 has been detected on various types of cells, including human carcinomas (90, 120) . ␣9␤1 promotes cell proliferation and migration when it interacts with tenascin, one of the components of the ECM (136), the gene for which is also upregulated (4.2-fold) by HMG-Y overexpression ( Table 2 ). The cellular effects of ␣9␤1 are mediated by phosphorylation and activation of the protein tyrosine kinase focal adhesion kinase (FAK) and the mitogen-activated kinase Erk2 (136) . Recent studies have shown that ␣9␤1 expressed on neutrophil cells interacts with VCAM-1, which is expressed on activated endothelial cells, and mediates neutrophil passage through the endothelial cell layer (105, 120) . The implication of these studies in terms of cancer progression is striking. Overexpression of ␣9␤1 in metastatic cells may well lead to tumor cells gaining extravasation capabilities and thus allow them to colonize various sites at the end state of the metastatic process. As with ␣9␤1, overexpression of ␣6␤1 can also contribute to cell proliferation and migration in mammary and prostate carcinomas (23, 80) . Overexpression of HMG-Y upregulates the integrin ␤1 subunit 10.7-fold and the integrin subunits ␣9, ␣6, and ␤1, 5.2-, 60.6-, and 10.7-fold, respectively ( Table 2) .
As diagrammed in Fig. 10 , these results support a model in which HMG-Y promotes tumor cell proliferation and metastasis, at least in part, through control of the level of expression of integrins and their signaling pathways. The following findings support such a model. Engagement of integrin ␤1-containing heterodimers activates ILK, a focal adhesion plaqueassociated serine/threonine protein kinase that is emerging as a key regulatory protein that functions at one of the early convergence points of integrin-and growth factor-stimulated signaling (25, 50) . The active form of ILK phosphorylates and activates PKB (also called Akt), a potent antiapoptosis enzyme that enable many types of tumors to evade programmed cell death (26, 32) . ILK also directly phosphorylates glycogen synthase kinase 3, glycogen synthesis kinase thereby inhibiting 3 activity and leading to a dramatic relocalization of ␤-catenin to the cell nucleus (124) . In the nucleus, ␤-catenin pairs with lymphoid enhancer factor 1 to form a complex that acts as an active transcription factor and plays an essential role in tumor progression (reviewed in reference 60). Interestingly, overexpression of ILK in epithelial cells leads to a complete EMT that is accompanied by a loss of cell-cell adhesions and an increase in vimentin expression (88, 133) . In addition, overexpression of ILK also leads to anchorage-independent cell growth, as determined by growth in soft agar, suppression of apoptosis, increased invasion of the ECM, and tumorigenicity in nude mice (50, 93) .
Heterodimers containing integrin ␤1 subunits are also know to be involved with activation of protein tyrosine kinase 2, the p38 MAPK, the focal adhesion kinase, and the Shc signaling pathways (reviewed in references 20, 41, and 127). Overexpression of integrins and the activation of one or more of the resulting signaling pathways are often associated with both tumor progression and increased metastatic potential of cancer cells (11, 72, 73, 106, 119) .
Integrins also regulate cell spreading, migration, and scattering through activation of the Rho family of proteins, GTPases that interact with multiple downstream effectors to control the actin cytoskeleton (47, 126) . Recent work by Clark et al. (21) has also demonstrated that overexpression of the wild-type RhoC protein alone induces a poorly metastatic human melanoma cell line to become highly metastatic when injected into nude mice whereas a dominant-negative Rho inhibits metastasis. Analysis of the phenotype of cells expressing dominant-negative Rho or RhoC indicated that the RhoC GTPase is important in invasion by tumor cells (21) . Importantly, as shown in Table 2 , overexpression of HMG-Y induces the upregulation of a number of Rho family proteins, including RhoC (3.9-fold), RhoG (3.7-fold) RhoGDI␥ (3.5-fold), and Rho-Rac G exchange factor (3.8-fold), a finding consistent with the proposed model the involvement of the HMGI(Y) proteins in the promotion of tumor metastasis (Fig. 10) .
Implications for human cancer. There are more than 100 distinct types of cancer in humans, and subtypes of tumors can be found in each specific organ. Available evidence suggests that cancer cells have defects in the regulatory mechanisms that govern normal cell proliferation and homeostasis. The complexity and variety of tumor types raise the question of how many distinct regulatory mechanisms within a normal cell must be disrupted in order for it to become cancerous. The current view is that tumorigenesis is a multstep process (i.e., the multihit theory) and that each step reflects a genetic alteration that drives the progressive transformation of normal human cells into highly malignant derivatives. However, all types of cancers have common hallmarks, i.e., have acquired several common capabilities (48) . Therefore, the simplicity elucidated from the complexity provokes another, even more important question i.e. whether there is an essential mechanism that is "hard wired" throughout all types of cancer? The cumulative results of numerous correlative studies have shown that HMGI(Y) genes are overexpressed in such diverse human epithelial tumor types as malignant prostate, breast, thyroid, and colon cancers, as well as aberrantly expressed in benign mesenchymal tumors such as a leiomyomas, adenomas, hamartomas, and lipomas. Recent studies employing gene expression array analyses of transcription profiles have also confirmed the overexpression of HMGI(Y) in biopsies of many human breast tumors (85, 92, 104 ). An even more interesting finding is that these array analyses also show that many of the genes listed in Table 2 (132) . These findings, coupled with the fact that mutations in the adenomatous polyposis coli tumor suppressor gene leads to overexpression of c-Myc and uncontrolled cell growth (52) , logically lead to a number of plausible multistep mechanisms that might explain the widespread involvement of HMGI(Y) in neoplastic transformation and metastatic progression. In one experimentally testable scenario, the initial tumor lesion is envisioned as a mutation in a tumor suppressor gene (e.g., adenomatous polyposis coli) which allows the aberrant expression or overexpression of one or more proto-oncogenes (e.g., c-myc) coding for transcription factors that can induce the promoter of the Hmgiy gene. These initial lesions might result in neoplastic transformation of the cells but not necessarily lead to permanent activation of the Hmgiy gene. Subsequent exposure of these mutation-containing cells to substances that promoter tumor progression (e.g., phorbol esters that activate AP-1 transcription factors) could then induce constitutive overexpression of the Hmgiy gene (c.f. reference 22), setting in motion a cascade of events leading to tumor progression and metastasis. Regardless of the actual sequence of molecular events involved, however, the present work demonstrates that the HMGI(Y) proteins are attractive targets for antitumor drug development and also for other, novel forms of cancer treatment.
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ADDENDUM
It has recently been reported (131) that Rat-1a fibroblast cells overexpressing either the HMG-I, HMG-Y, or HMGI-C protein form tumors and distant metastases when injected into nude mice.
